FOSUN PHARMA (02196.HK): Sells 6% Stake in India's Gland Pharma for Approximate USD 294 Million

NewTimeSpace News: On 6 September 2026, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 02196) announced that on 4 September 2026 (India time) its controlling subsidiary Fosun Pharma Singapore sold a total of 9.897 million Gland Pharma shares through block trades and competitive bidding, representing approximately 6.00% of Gland Pharma's total share count. Total consideration (before transaction commission and tax) was INR 27.996 billion (approximately USD 294 million), at an average price of INR 2,828.78 per share, a discount of approximately 2.72% to the previous trading day's closing price. Settlement is expected on 7 September 2026 (India time).

Following the transaction, the group's equity interest in Gland Pharma decreases from 51.76% to approximately 45.76%, and it remains the controlling shareholder, with Gland Pharma continuing to be included in the group's consolidated reporting. Proceeds will be applied to R&D investment, share buybacks and repayment of interest-bearing debt, and will increase the group's net assets. As a partial disposal of the controlling subsidiary, the proceeds will not be recorded as investment income in the group's income statement, with the actual financial impact subject to audit.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.